Related Experiment Videos
Treatment of experimental Escherichia coli infection in mice with colicine V
Abstract:
Concentrated non-toxic preparations of colicine V were obtained by filtering centrifugates of soft-agar cultures of a Col V+ K12 strain of E. coli through Millipore filters in which the colicine V was retained. These preparations, given subcutaneously, favourably influenced the course of disease in mice infected intraperitoneally with a pathogenic strain of E. coli that was very sensitive to colicine V in vitro. A beneficial effect was noted even when treatment was delayed until the mice were visibly ill.
Insights
Concentrated colicin V preparations showed therapeutic potential against E. coli infections in mice. Subcutaneous administration of this non-toxic colicin V demonstrated a beneficial effect, even in visibly ill animals.
Area of Science:
- Microbiology
- Immunology
- Pharmacology
Background:
- Escherichia coli (E. coli) infections pose a significant health risk.
- Colicins are bacteriocins produced by E. coli with antimicrobial properties.
- Colicin V (Col V) has shown in vitro activity against pathogenic E. coli strains.
Purpose of the Study:
- To investigate the therapeutic efficacy of concentrated colicin V preparations in a mouse model of E. coli infection.
- To determine if colicin V treatment can favorably influence the course of disease.
- To assess the effectiveness of colicin V when administered after disease onset.
Main Methods:
- Concentrated, non-toxic colicin V preparations were obtained using Millipore filtration of E. coli K12 soft-agar cultures.
- Mice were infected intraperitoneally with a pathogenic E. coli strain sensitive to colicin V.
- Subcutaneous administration of colicin V preparations was performed.
Main Results:
- Subcutaneous administration of concentrated colicin V favorably influenced the disease course in infected mice.
- A beneficial effect was observed even when colicin V treatment was initiated in visibly ill mice.
- The pathogenic E. coli strain used was highly sensitive to colicin V in vitro.
Conclusions:
- Concentrated colicin V preparations exhibit therapeutic potential against E. coli infections.
- Colicin V demonstrates efficacy as a treatment for E. coli infections in a murine model.
- The findings suggest colicin V as a viable therapeutic agent, even in advanced stages of infection.